Aurora Spine Announces Full Release of its SiLO TFX™ MIS Sacroiliac Joint Fixation System
2023年9月13日 - 8:15PM
Aurora Spine Corporation (“Aurora Spine” or the “Company”)
(TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of
innovative medical devices that improve spinal surgery outcomes,
announced today that it is in full commercial release of its
proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device
system.
The patented, minimally invasive SiLO TFX MIS
Sacroiliac Joint Fixation System is intended for sacroiliac joint
fusion for conditions including sacroiliac joint disruptions and
degenerative sacroiliitis. The SiLO TFX MIS Sacroiliac Joint
Fixation System includes a Transfixing-Cone, an ilium screw, a
sacrum screw and associated instrumentation. The SiLO TFX implants
are designed to transfix the sacrum and ilium, providing stability
for bony fusion.
Mr. Trent Northcutt, Aurora’s President, CEO and
co-founder, stated, "We are excited to be in full launch of our
game changing treatment for patients suffering with SI Joint pain
and disfunction.”
Petra Lopizzo, Aurora’s Director of Operations,
said “The release of SiLO TFX is proceeding smoothly and rapidly as
we deploy more instruments sets and implants into the
field. I am pleased with the teamwork between
Engineering, Operations and Marketing on the full release of the
SiLO TFX system."
About Aurora Spine
Aurora Spine is focused on bringing new
solutions to the spinal implant market through a series of
innovative, minimally invasive, regenerative spinal implant
technologies. Additional information can be accessed at
www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking
information that involves substantial known and unknown risks and
uncertainties, most of which are beyond the control of Aurora
Spine, including, without limitation, those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking
Information" in Aurora Spine's final prospectus (collectively,
"forward-looking information"). Forward-looking information in this
news release includes information concerning the proposed use and
success of the company’s products in surgical procedures. Aurora
Spine cautions investors of Aurora Spine's securities about
important factors that could cause Aurora Spine's actual results to
differ materially from those projected in any forward-looking
statements included in this news release. Any statements that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance are
not historical facts and may be forward-looking and may involve
estimates, assumptions and uncertainties which could cause actual
results or outcomes to differ unilaterally from those expressed in
such forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and,
accordingly, prospective investors should not place undue reliance
on these forward-looking statements. These statements speak only as
of the date of this press release and Aurora Spine does not assume
any obligation to update or revise them to reflect new events or
circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
asapf@lythampartners.com
Aurora Spine (TSXV:ASG)
過去 株価チャート
から 4 2024 まで 5 2024
Aurora Spine (TSXV:ASG)
過去 株価チャート
から 5 2023 まで 5 2024